LONDON – In a Franco-Sino tie-up Pharnext SA and Tasly Pharmaceutical Co. Ltd. signed a three-part agreement, which will see the Chinese pharma invest up to $44 million in a combination of equity, a joint venture, and the clinical development of Pharnext's lead program, PXT-3003, in China.